Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Recce PharmaceuticalsASX:RCE -1.30%25 9-Day RSI is 39.10 as of Jul. 19, 2026. GuruFocus rates ASX:RCE with a GF Score™ of 25/100. The stock has 4 warning signs investors should review. Among 1,423 Biotechnology companies, Recce Pharmaceuticals ranks better than 67.74% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Recce Pharmaceuticals 9-Day RSI Related Terms
ASX:RCE vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, Recce Pharmaceuticals's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recce Pharmaceuticals 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Recce Pharmaceuticals's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Recce Pharmaceuticals's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recce Pharmaceuticals (ASX:RCE) has a 9-Day RSI of 39.10 as of Jul. 19, 2026. According to the industry distribution chart, Recce Pharmaceuticals ranks #459 out of 1423 companies in the Biotechnology industry, placing it in the top 32.3%.
Is Recce Pharmaceuticals' 9-Day RSI too high?
Recce Pharmaceuticals' current 9-Day RSI is 39.10. The Biotechnology industry median 9-Day RSI is 44.39. Recce Pharmaceuticals' value of 39.10 is 11.9% below this industry median. Based on the distribution chart, Recce Pharmaceuticals ranks #459 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Recce Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Recce Pharmaceuticals' 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Recce Pharmaceuticals ranks #459 out of 1423 companies for 9-Day RSI. This puts Recce Pharmaceuticals in the upper half of its industry. The industry median 9-Day RSI is 44.39. Recce Pharmaceuticals' value of 39.10 is 11.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 44.39, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recce Pharmaceuticals's current 9-Day RSI of 39.10 is 11.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 44.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recce Pharmaceuticals's current 9-Day RSI is 39.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recce Pharmaceuticals stock overvalued right now?
Recce Pharmaceuticals (ASX:RCE) has a current 9-Day RSI of 39.10. The current 9-Day RSI is 39.10 and 11.9% below the Biotechnology industry median of 44.39. Recce Pharmaceuticals' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Recce Pharmaceuticals (ASX:RCE), the current 9-Day RSI is 39.10 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.
25GF Score
Get the complete analysis for ASX:RCE
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RCE has been successfully added to your 
